Skip to content

Financial Information

This section of the Karyopharm Therapeutics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 

Please note:  All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes.  Karyopharm Therapeutics assumes no responsibility for the accuracy of this data and provides it for informational purposes only.

NASDAQKPTI
Beta(0.01)
Shares Outstanding114.4M
Average Volume (10 days)1.1M
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($1.46)
Sales (TTM)$0.33
Book Value (MRQ)($0.62)
Cash Flow (TTM)($0.71)
Cash (MRQ)$2.08

Analyst Views

Current Mean RecommendationBuy
Strong Buy4
 
Buy1
 
Hold4
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Bohlin Garen
Director
41,140
Buy
Sep 12, 2023
Su Zhen
68,000
Acquire
Aug 31, 2023
Paulson Richard
Ceo/President
(3,722)
Sell
Aug 7, 2023
Poulton Stuart
EVP, Chief Development Officer
(2,845)
Sell
Jul 28, 2023
Cheng Sohanya
Chief Commercial Officer
(1,839)
Sell
Jun 8, 2023

Recent SEC Filings

Insider Buy/Sell
Sep 12, 2023
Insider Buy/Sell
Sep 6, 2023
Insider Buy/Sell
Sep 5, 2023
Insider Buy/Sell
Sep 5, 2023
Insider Buy/Sell
Sep 5, 2023
I agree to the storing and processing of my personal data by Karyopharm as described in the Privacy Policy and to the Terms of Use . I agree to receive communications from Karyopharm and understand that I can unsubscribe at any time.